Stuart Therapeutics announces first patient visit in ST-100 trial for dry eye

Stuart Therapeutics has announced the first patient first visit for its phase 3 clinical trial of ST-100 ophthalmic solution for patients with dry eye disease.
According to a company press release, ST-100 (vezocolmitide) is the first drug candidate based on PolyCol, the company’s synthesized polypeptide technology that mimics amino acid sequences found in collagen.
“We believe that vezocolmitide has the potential to solve the major unmet need for a fast and effective topical therapeutic that treats a broad range of dry eye disease patients,” Eric Schlumpf, Stuart’s

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart